Spots Global Cancer Trial Database for cytokine release syndrome
Every month we try and update this database with for cytokine release syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | NCT06421675 | Refractory Mult... | Elranatamab inj... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | NCT04150913 | Non Hodgkin Lym... Refractory Non-... Relapsed Non Ho... Neurotoxicity Neurotoxicity S... Cytokine Releas... | Anakinra Axicabtagene Ci... | 18 Years - | Massachusetts General Hospital | |
| Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome | NCT05510596 | Lymphoma, B-Cel... Neurotoxicity | Magnetic Resona... Blood withdrawa... Neuropsychologi... | 18 Years - | University Hospital, Montpellier | |
| Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome | NCT05510596 | Lymphoma, B-Cel... Neurotoxicity | Magnetic Resona... Blood withdrawa... Neuropsychologi... | 18 Years - | University Hospital, Montpellier | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | NCT06352866 | Multiple Myelom... Cytokine Releas... Refractory Mult... Immune Effector... | Siltuximab Teclistamab(FDA... | 18 Years - | Case Comprehensive Cancer Center | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Phase I Trial of Anti-GD2 T-cells (1RG-CART) | NCT02761915 | Relapsed or Ref... | Leukapheresis Cyclophosphamid... Fludarabine 1RG-CART | 1 Year - | Cancer Research UK | |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | NCT06421675 | Refractory Mult... | Elranatamab inj... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | NCT05414162 | DLBCL Multiple Myelom... Cytokine Releas... Myocarditis CAR T-cell Ther... ALL PCBCL Follicular Lymp... MCL | Cardiac MRI | 18 Years - | University Hospital, Bonn |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
